WRAPSODY Device Patent Review Locked in by FDA
Published Date: 2/26/2026
Notice
Summary
The FDA has officially set the review period for the MERIT MEDICAL WRAPSODY device, which helps extend its patent protection. This means the company can apply for extra patent time, giving them more control over their invention. If anyone thinks the dates are wrong or the company wasn’t careful during the review, they can speak up by April or August 2026.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Applicant requests 908‑day patent extension
Merit Medical Systems filed patent-term restoration applications for U.S. Patent Nos. 10,005,269 and 10,028,852 and, in its USPTO application, seeks 908 days of patent term extension. The FDA notes its determination establishes the maximum potential length, and the USPTO will apply statutory limitations when calculating the actual extension.
FDA sets WRAPSODY review period
The FDA determined the regulatory review period for MERIT MEDICAL WRAPSODY is 1,639 days total, including 1,462 days of testing and 177 days of approval. Key dates the FDA verified are: investigational device exemption effective June 26, 2020; premarket approval (PMA P240023) submitted June 26, 2024; and PMA approval on December 19, 2024.
Public comment and petition deadlines
Anyone who believes the published dates are incorrect may ask FDA for a redetermination by April 27, 2026. Any interested person who believes the applicant did not act with due diligence during the regulatory review period may petition FDA by August 25, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-03852 — Agency Information Collection Activity Under OMB Review: Intent To File a Claim for Compensation and/or Pension, or Survivors Pension and/or DIC
The VA is asking for public feedback on a form veterans use to say they plan to file for benefits like compensation or pension. This form helps set the start date for benefits, but no changes have been made to it—just more people are expected to use it. If you’re a veteran or survivor thinking about benefits, now’s the time to weigh in before March 30, 2026!
Next: 2026-03854 — Notice and Request for Comment; Proposal for a New United Nations Global Technical Regulation on Automated Driving Systems (ADS)
The U.S. government wants your thoughts on a new global rule for self-driving cars to make sure they’re safe and work well. This affects car makers, tech companies, and anyone interested in automated driving. You’ve got until March 10, 2026, to share your ideas—no extra costs, just your voice helping shape the future of driving!